Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029916 | 0.92 | HRH3 (0.39) | PDE4APDE4BPDE4CPDE4DHRH3 | |
| SCHEMBL5031836 | 0.88 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DHRH3 | |
| SCHEMBL5030048 | 0.86 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DHRH3 | |
| SCHEMBL5037109 | 0.86 | TP53 (0.41) | — | |
| SCHEMBL5037190 | 0.85 | ALDH1A1 (0.39) | — | |
| SCHEMBL5031993 | 0.85 | HPGD (0.42) | P2RX7 | |
| SCHEMBL5034450 | 0.79 | ALDH1A1 (0.39) | S1PR3 | |
| SCHEMBL5032927 | 0.79 | ALDH1A1 (0.43) | — | |
| SCHEMBL6888818 | 0.78 | HTT (0.43) | — | |
| SCHEMBL5029835 | 0.78 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | PDE4A 1570/4885PDE4B 1844/4885PDE4C 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.